Literature DB >> 8953819

Adverse drug reactions with fluoroquinolones.

R J Royer1.   

Abstract

The French system of drug surveillance has analysed the notifications of adverse drug reactions (ADRs) to fluoroquinolones since they were launched. Their frequency ranges from 1/15,000 to 1/208,000 case per days of treatment. Cutaneous diseases and tendon disorders predominate in France whereas cutaneous effects and neuropsychiatric disorders are predominant in the UK; tendon disorders take up only the 5th position. Among the most unexpected ADRs are the following: -shock represents 33 of the anaphylaxis reactions which range from 1/5.6 x 10(6) to 1/4.4 x 10(5) case per days of treatment. -acute renal failure is rare: one case/80,000 patients treated by ciprofloxacin to 1/320,000 by norfloxacin. The pathophysiology is not well known. Tendon ruptures represent 81 cases for 921 notifications of tendon disorders which are related in decreasing order to pefloxacin 1/23,130 case per days of treatment, ofloxacin, norfloxacin and ciprofloxacin 1/779,600 case per days of treatment. Age and corticosteroids increase the risk of tendon rupture.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953819

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  5 in total

1.  Prophylactic treatment of anthrax with antibiotics.

Authors:  C A Hart; N J Beeching
Journal:  BMJ       Date:  2001-11-03

2.  The link between sunshine and phototoxicity of sparfloxacin.

Authors:  C Pierfitte; R J Royer; N Moore; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

3.  Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study.

Authors:  L Letrilliart; T Hanslik; M Biour; J P Fagot; M Guiguet; A Flahault
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Levofloxacin, tendon rupture and acute kidney injury: Thinking outside the box.

Authors:  S Senthilkumaran; S Shah; N Balamurugan; P Thirumalaikolundusubramanian
Journal:  Indian J Nephrol       Date:  2012-01

5.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study.

Authors:  Heino Stass; John Lettieri; Konstantina M Vanevski; Stefan Willmann; Laura P James; Janice E Sullivan; Antonio C Arrieta; John S Bradley
Journal:  J Clin Pharmacol       Date:  2019-01-25       Impact factor: 2.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.